Mere weeks after being named the nation’s top drug regulator, Richard Pazdur, M.D., is taking steps to retire as head of the FDA’s Center for Drug Evaluation and Research at the end of this month, | ...
Longtime FDA oncology leader and newly appointed Center for Drug Evaluation and Research director Richard Pazdur has filed ...
A longtime FDA official who took over last month as the agency’s top drug regulator intends to retire.The departure of ...
The U.S. Food and Drug Administration's drug evaluation chief, Richard Pazdur, is set to retire just weeks after taking the ...
Food and Drug Administration chief Marty Makary convinced Rick Pazdur to take the role to help bring stability to the roiling agency.
Richard Pazdur, the US Food and Drug Administration’s lead drug regulator, plans to retire from the agency only weeks after ...
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire from the agency. The seven-year FDA veteran communicated the decision in an ...
Drug development for rare diseases can be challenging for a number of reasons, including clinical trial design challenges, clinical trial recruitment, interpretation of clinical trial data in view of ...
In January 2024, the Office of Compliance at the FDA’s Center for Drug Evaluation Research (CDER) released its Annual Report for FY2023. The Annual Report contains several useful pieces of information ...
Richard Pazdur, the US Food and Drug Administration’s lead drug regulator, plans to retire from the agency only weeks after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback